Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Glibenclamide Inhibits the Contractile Responses of Canine Middle Cerebral Artery to Eicosanoids and Oxyhemoglobin

      Read this article at

      ScienceOpenPublisher
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Glibenclamide is a sulfonylurea used in the management of diabetes mellitus but which is also known to have antagonist activity against the effects of some eicosanoids on smooth muscle. We have examined the action of glibenclamide against contractions of rings of canine middle cerebral artery by prostaglandins F<sub>2α</sub>, E<sub>2</sub> and D<sub>2</sub> and the thromboxane A<sub>2</sub> analog U46619. All these responses were significantly attenuated by glibenclamide, while contractions to potassium chloride, noradrenaline, 5-hydroxytryptamine or caffeine were unaffected. The effects of glibenclamide against the vascular actions of oxyhemoglobin were also examined, since this agent is believed to be responsible for the vasospasm which follows subarachnoid hemorrhage. Contractions to oxyhemoglobin were significantly inhibited by glibenclamide, which suggests that at least part of the contractile effects of oxyhemoglobin in cerebral arteries is mediated by eicosanoids. Glibenclamide is thus an agent which selectively blocks the contractile effects of both eicosanoids and oxyhemoglobin.

          Related collections

          Author and article information

          Journal
          CED
          Cerebrovasc Dis
          10.1159/issn.1015-9770
          Cerebrovascular Diseases
          S. Karger AG
          1015-9770
          1421-9786
          1992
          1992
          04 March 1992
          : 2
          : 1
          : 51-57
          Affiliations
          a Department of Surgery, b Department of Pharmacology, University of Alberta, Edmonton, Canada
          Article
          108989 Cerebrovasc Dis 1992;2:51–57
          10.1159/000108989
          © 1992 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 7
          Categories
          Original Paper

          Comments

          Comment on this article